|
AU2003225410A1
(en)
*
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
EP1629105B1
(en)
|
2003-04-29 |
2010-09-01 |
AVI BioPharma, Inc. |
Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
|
|
US20050222068A1
(en)
*
|
2003-10-23 |
2005-10-06 |
Mourich Dan V |
Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
|
|
AU2005208710A1
(en)
*
|
2004-01-23 |
2005-08-11 |
Avi Biopharma, Inc. |
Antisense oligomers and methods for inducing immune tolerance and immunosuppression
|
|
US20050288246A1
(en)
|
2004-05-24 |
2005-12-29 |
Iversen Patrick L |
Peptide conjugated, inosine-substituted antisense oligomer compound and method
|
|
PL1766010T3
(pl)
|
2004-06-28 |
2011-07-29 |
Univ Western Australia |
Antysensowne oligonukleotydy do indukcji pominięcia egzonu i sposoby ich zastosowania
|
|
US8129352B2
(en)
|
2004-09-16 |
2012-03-06 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating ssRNA viral infection
|
|
EP1855694B1
(en)
|
2005-02-09 |
2020-12-02 |
Sarepta Therapeutics, Inc. |
Antisense composition for treating muscle atrophy
|
|
US8067571B2
(en)
|
2005-07-13 |
2011-11-29 |
Avi Biopharma, Inc. |
Antibacterial antisense oligonucleotide and method
|
|
WO2007030691A2
(en)
*
|
2005-09-08 |
2007-03-15 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating picornavirus infection
|
|
US8168181B2
(en)
|
2006-02-13 |
2012-05-01 |
Alethia Biotherapeutics, Inc. |
Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
|
|
DK1994155T4
(da)
|
2006-02-13 |
2022-07-25 |
Daiichi Sankyo Co Ltd |
Polynukleotid- og polypeptidsekvenser involveret i fremgangsmåden med knogleremodellering
|
|
US8785407B2
(en)
*
|
2006-05-10 |
2014-07-22 |
Sarepta Therapeutics, Inc. |
Antisense antiviral agent and method for treating ssRNA viral infection
|
|
US20100016215A1
(en)
|
2007-06-29 |
2010-01-21 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
CN101896186A
(zh)
|
2007-10-26 |
2010-11-24 |
莱顿教学医院 |
对抗肌肉病症的方式和方法
|
|
EP2235034B1
(en)
*
|
2007-12-28 |
2016-11-23 |
Sarepta Therapeutics, Inc. |
Immunomodulatory agents and methods of use
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
US8231895B2
(en)
|
2008-05-22 |
2012-07-31 |
Universidade De Coimbra |
Targeted delivery to human diseases and disorders
|
|
US20110130346A1
(en)
*
|
2008-05-30 |
2011-06-02 |
Isis Innovation Limited |
Peptide conjugates for delvery of biologically active compounds
|
|
EP2283029A1
(en)
*
|
2008-06-04 |
2011-02-16 |
Medical Research Council |
Peptides
|
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
SMT201900159T1
(it)
*
|
2008-10-24 |
2019-05-10 |
Sarepta Therapeutics Inc |
Composizioni di salto di esone per dmd
|
|
WO2010080554A1
(en)
*
|
2008-12-17 |
2010-07-15 |
Avi Biopharma, Inc. |
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
|
|
CA2759899A1
(en)
|
2009-04-24 |
2010-10-28 |
Prosensa Technologies B.V. |
Oligonucleotide comprising an inosine for treating dmd
|
|
US20110269665A1
(en)
|
2009-06-26 |
2011-11-03 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
KR20230137491A
(ko)
|
2009-11-12 |
2023-10-04 |
더 유니버시티 오브 웨스턴 오스트레일리아 |
안티센스 분자 및 이를 이용한 질환 치료방법
|
|
CN102712928B
(zh)
|
2009-11-13 |
2017-08-04 |
萨雷普塔治疗公司 |
反义抗病毒化合物及治疗流感病毒感染的方法
|
|
JP5677454B2
(ja)
*
|
2009-12-11 |
2015-02-25 |
グワンジュ・インスティテュート・オブ・サイエンス・アンド・テクノロジー |
細胞内ターゲット結合用二座ペプチドバインダー
|
|
US9006415B2
(en)
*
|
2010-04-06 |
2015-04-14 |
Massachusetts Institute Of Technology |
Targeted delivery of nucleic acids
|
|
US9050373B2
(en)
|
2010-05-13 |
2015-06-09 |
The Charlotte-Mecklenburg Hospital Authority |
Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
|
|
NZ603606A
(en)
|
2010-05-28 |
2015-06-26 |
Sarepta Therapeutics Inc |
Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
|
|
AU2011282217B2
(en)
*
|
2010-07-19 |
2015-12-03 |
Ionis Pharmaceuticals, Inc. |
Modulation of dystrophia myotonica-protein kinase (DMPK) expression
|
|
US8198429B2
(en)
|
2010-08-09 |
2012-06-12 |
Avi Biopharma, Inc. |
Antisense antiviral compounds and methods for treating a filovirus infection
|
|
JP6478632B2
(ja)
*
|
2011-05-05 |
2019-03-06 |
サレプタ セラピューティクス， インコーポレイテッド |
ペプチドオリゴヌクレオチドコンジュゲート
|
|
US9161948B2
(en)
|
2011-05-05 |
2015-10-20 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
IN2014MN00357A
(OSRAM)
|
2011-08-30 |
2015-06-19 |
Medical Res Council |
|
|
EP2750715B1
(en)
|
2011-08-30 |
2018-10-31 |
The Regents of The University of California |
Identification of small molecules that enhance therapeutic exon skipping
|
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
|
PT2581448E
(pt)
*
|
2011-10-13 |
2015-05-21 |
Institut National De La Santé Et De La Rech Médicale (Inserm) |
Dna triciclo-fosforotioato
|
|
TR201809173T4
(tr)
*
|
2011-12-08 |
2018-07-23 |
Sarepta Therapeutics Inc |
İnsan LMNA'sını hedef alan oligonükleotid analogları.
|
|
BR112014018427B1
(pt)
*
|
2012-01-27 |
2021-11-03 |
Biomarin Technologies B.V. |
Oligonucleotídeos moduladores de rna com características melhoradas para o tratamento da distrofia muscular de duchenne e becker
|
|
AU2013262709A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
KR20160074368A
(ko)
*
|
2012-05-16 |
2016-06-28 |
라나 테라퓨틱스, 인크. |
Utrn 발현을 조절하기 위한 조성물 및 방법
|
|
EA201492120A1
(ru)
|
2012-05-16 |
2015-10-30 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии atp2a2
|
|
WO2013173638A1
(en)
*
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating smn gene family expression
|
|
BR112014028631A2
(pt)
|
2012-05-16 |
2017-10-17 |
Rana Therapeutics Inc |
composições e métodos para modulação da expressão da família de genes da hemoglobina
|
|
KR101329411B1
(ko)
|
2012-05-31 |
2013-11-14 |
주식회사 엘지생활건강 |
피부투과성 펩타이드
|
|
US9493562B2
(en)
|
2012-07-19 |
2016-11-15 |
Alethia Biotherapeutics Inc. |
Anti-Siglec-15 antibodies
|
|
CA3211094A1
(en)
|
2012-08-13 |
2014-02-20 |
The Rockefeller University |
Treatment and diagnosis of melanoma
|
|
KR102240217B1
(ko)
*
|
2012-09-25 |
2021-04-14 |
젠자임 코포레이션 |
근긴장성 이영양증의 치료용 펩티드-결합 모르폴리노 안티센스 올리고뉴클레오티드
|
|
CA2889044A1
(en)
|
2012-11-15 |
2014-05-22 |
Roche Innovation Center Copenhagen A/S |
Anti apob antisense conjugate compounds
|
|
CN103981147B
(zh)
|
2013-02-08 |
2017-11-10 |
中国科学院上海生命科学研究院 |
一种新的制备肝实质细胞的方法
|
|
NZ631245A
(en)
|
2013-03-14 |
2017-09-29 |
Sarepta Therapeutics Inc |
Exon skipping compositions for treating muscular dystrophy
|
|
HK1220154A1
(zh)
|
2013-03-15 |
2017-04-28 |
Sarepta Therapeutics, Inc. |
改进的用於治疗肌营养不良的组合物
|
|
EP3065783A4
(en)
|
2013-11-06 |
2017-06-21 |
Merck Sharp & Dohme Corp. |
Dual molecular delivery of oligonucleotides and peptide containing conjugates
|
|
CA2948373A1
(en)
|
2014-05-16 |
2015-11-19 |
Oregon State University |
Antisense antibacterial compounds and methods
|
|
AU2015264449B2
(en)
|
2014-05-19 |
2022-05-05 |
Board Of Regents, The University Of Texas System |
Antisense antibacterial compounds and methods
|
|
SG10202004611SA
(en)
|
2014-05-23 |
2020-06-29 |
Genzyme Corp |
Multiple oligonucleotide moieties on peptide carrier
|
|
EP3146050B1
(en)
|
2014-05-23 |
2020-08-12 |
Genzyme Corporation |
Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides
|
|
US11293024B2
(en)
|
2014-12-31 |
2022-04-05 |
Board Of Regents, The University Of Texas System |
Antisense antibacterial compounds and methods
|
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
|
US11020417B2
(en)
|
2015-06-04 |
2021-06-01 |
Sarepta Therapeutics, Inc |
Methods and compounds for treatment of lymphocyte-related diseases and conditions
|
|
EP3359668A4
(en)
*
|
2015-10-09 |
2019-06-05 |
Sarepta Therapeutics, Inc. |
COMPOSITIONS AND METHODS OF TREATING DUCHENNE MUSCLE DYSTROPHY AND ASSOCIATED ILLNESSES THEREOF
|
|
EP3394261A4
(en)
|
2015-12-23 |
2019-11-27 |
Oregon State University |
ANTIBACTERIAL ANTISENSE COMPOUNDS AND METHOD
|
|
EP3394262B1
(en)
|
2015-12-23 |
2024-08-28 |
Oregon State University |
Antisense antibacterial compounds and methods
|
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
|
WO2017184529A1
(en)
|
2016-04-18 |
2017-10-26 |
Sarepta Therapeutics, Inc. |
Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
|
|
SG11201809468XA
(en)
|
2016-04-29 |
2018-11-29 |
Sarepta Therapeutics Inc |
Oligonucleotide analogues targeting human lmna
|
|
MD3554554T2
(ro)
|
2016-12-19 |
2022-12-31 |
Sarepta Therapeutics Inc |
Conjugați de oligomeri de omitere a exonului, pentru distrofie musculară
|
|
US10800817B2
(en)
*
|
2016-12-19 |
2020-10-13 |
Morehouse School Of Medicine |
Compositions and methods for treating diseases by inhibiting exosome release
|
|
SG10202012839TA
(en)
|
2016-12-19 |
2021-01-28 |
Sarepta Therapeutics Inc |
Exon skipping oligomer conjugates for muscular dystrophy
|
|
BR112019012664A2
(pt)
|
2016-12-19 |
2020-01-21 |
Sarepta Therapeutics Inc |
conjugados de oligômero de salto de éxon para distrofia muscular
|
|
MX2019008199A
(es)
|
2017-01-06 |
2019-11-25 |
Avidity Biosciences Llc |
Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
|
|
US20180207293A1
(en)
*
|
2017-01-25 |
2018-07-26 |
2C Tech Corp. |
Nanoparticles for sustained ophthalmic drug delivery and methods of use
|
|
GB201711809D0
(en)
*
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
JP2020536060A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
|
JP2020536057A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
|
EP3687577A1
(en)
|
2017-09-28 |
2020-08-05 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
|
WO2019079386A1
(en)
*
|
2017-10-17 |
2019-04-25 |
Sarepta Therapeutics, Inc. |
CELL PENETRATION PEPTIDES FOR ANTISENSE ADMINISTRATION
|
|
EP3713575A4
(en)
|
2017-11-21 |
2021-08-25 |
Rgenix, Inc. |
POLYMORPHS AND THEIR USES
|
|
JP7013626B2
(ja)
*
|
2018-01-05 |
2022-02-01 |
国立医薬品食品衛生研究所長 |
細胞膜透過ペプチド、構築物、及び、カーゴ分子を細胞内に輸送する方法
|
|
EP3790890A4
(en)
|
2018-05-09 |
2022-03-02 |
Ohio State Innovation Foundation |
CYCLIC PEPTIDES OF CELL PENETRATION WITH ONE OR MORE HYDROPHOBIC RESIDUES
|
|
EP3806868A4
(en)
|
2018-06-13 |
2022-06-22 |
Sarepta Therapeutics, Inc. |
EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
|
|
TW202020153A
(zh)
|
2018-07-27 |
2020-06-01 |
美商薩羅塔治療公司 |
用於肌肉萎縮症之外顯子跳躍寡聚物
|
|
EP3829596A4
(en)
*
|
2018-08-02 |
2022-05-11 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF MYOTONIC DYSTROPHY
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
GB201812980D0
(en)
|
2018-08-09 |
2018-09-26 |
Univ Oxford Innovation Ltd |
Cell-penetrating peptides
|
|
GB201812972D0
(en)
|
2018-08-09 |
2018-09-26 |
Univ Oxford Innovation Ltd |
Cell-penetrating peptides
|
|
CN113453723A
(zh)
|
2018-12-07 |
2021-09-28 |
牛津大学科技创新有限公司 |
接头
|
|
IL318474A
(en)
|
2018-12-13 |
2025-03-01 |
Sarepta Therapeutics Inc |
Axon-skipping oligomer complexes for muscular dystrophy
|
|
GB201821269D0
(en)
|
2018-12-28 |
2019-02-13 |
Nippon Shinyaku Co Ltd |
Myostatin signal inhibitor
|
|
EP3955966A1
(en)
|
2019-04-18 |
2022-02-23 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
|
GB201911403D0
(en)
*
|
2019-08-09 |
2019-09-25 |
Univ Oxford Innovation Ltd |
Conjugate and uses thereof
|
|
KR102270700B1
(ko)
*
|
2019-11-01 |
2021-06-30 |
한국과학기술연구원 |
폐 섬유증의 예방 또는 치료를 위한 올리고뉴클레오티드 중합체와 생체 적합성 양이온성 펩타이드로 이루어지는 폐 특이적 약물 전달체 및 이의 이용
|
|
HUE067466T2
(hu)
|
2019-12-13 |
2024-10-28 |
Inspirna Inc |
Fémsók és alkalmazásuk
|
|
KR20220122673A
(ko)
|
2019-12-26 |
2022-09-02 |
니뽄 신야쿠 가부시키가이샤 |
엑손 50의 스키핑을 유도하는 안티센스 핵산
|
|
JPWO2021172498A1
(OSRAM)
|
2020-02-28 |
2021-09-02 |
|
|
|
US11987795B2
(en)
|
2020-11-24 |
2024-05-21 |
The Broad Institute, Inc. |
Methods of modulating SLC7A11 pre-mRNA transcripts for diseases and conditions associated with expression of SLC7A11
|
|
JP2024501800A
(ja)
|
2020-12-23 |
2024-01-16 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを治療するためのエクソンスキッピングオリゴヌクレオチドコンジュゲートを含む組成物
|
|
KR20240004609A
(ko)
|
2021-04-30 |
2024-01-11 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
근이영양증에 대한 치료 방법
|
|
US12378267B2
(en)
|
2021-06-17 |
2025-08-05 |
Entrada Therapeutics, Inc. |
Synthesis of FMOC-protected morpholino monomers and oligomers
|
|
MX2023014417A
(es)
|
2021-06-23 |
2023-12-15 |
Nippon Shinyaku Co Ltd |
Combinacion de oligomeros antisentido.
|
|
JPWO2023282346A1
(OSRAM)
|
2021-07-08 |
2023-01-12 |
|
|
|
KR20240035502A
(ko)
|
2021-07-08 |
2024-03-15 |
니뽄 신야쿠 가부시키가이샤 |
신독성 경감제
|
|
EP4368176A4
(en)
|
2021-07-08 |
2025-06-25 |
Nippon Shinyaku Co., Ltd. |
Nephrotoxicity reducing agent
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US20250011777A1
(en)
*
|
2021-09-03 |
2025-01-09 |
Sarepta Therapeutics, Inc. |
Delivery of anitsense oligomers by mirror image peptides
|
|
EP4493693A1
(en)
|
2022-03-17 |
2025-01-22 |
Sarepta Therapeutics, Inc. |
Phosphorodiamidate morpholino oligomer conjugates
|
|
AU2023254846A1
(en)
|
2022-04-15 |
2024-10-10 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating myotonic dystrophy
|
|
US20250289851A1
(en)
|
2022-04-22 |
2025-09-18 |
Entrada Therapeutics, Inc. |
Cyclic peptides for delivering therapeutics
|
|
WO2024091824A1
(en)
|
2022-10-26 |
2024-05-02 |
Ada Forsyth Institute, Inc. |
Differentiation and reprogramming of chondrocyte
|
|
EP4612292A1
(en)
|
2022-11-02 |
2025-09-10 |
Sarepta Therapeutics, Inc. |
Formulation of an antisense oligomer conjugate
|
|
EP4634373A1
(en)
|
2022-12-16 |
2025-10-22 |
University of Rochester |
Repairment of barrier dysfunction in esophagus
|
|
WO2025085868A2
(en)
|
2023-10-20 |
2025-04-24 |
Radiation Control Technologies, Inc. |
Cd47-targeting morpholinos
|